A
A

AstraZeneca


خبر

Financial Times - Jan 30

PRESS DIGEST- Financial Times - Jan 30 Jan 30 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - RQ Bio partners with AstraZeneca in COVID antibody fight - Nuclear industry calls for new UK reactors as 'matter of priority' - Rio Tinto apologises for losing highly radioactive capsule - BP cuts long-term forecast for oil and gas demand Overview - AstraZeneca AZN.L moved to bolster its COVID
A
B
R

UK Stocks-Factors to watch on Jan 27

UPDATE 1-UK Stocks-Factors to watch on Jan 27 Adds news items, updates futures Jan 27 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher with futures FFIc1 up 0 .1% on Friday. * SUPERDRY: Britain's Superdry SDRY.L cut its profit forecast for the year and now expects to broadly break even as its wholesale segment underperformed amid rising uncertainty for the last quarter.
A
D
R

UK Stocks-Factors to watch on Jan 27

UK Stocks-Factors to watch on Jan 27 Jan 27 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher with futures FFIc1 up 0.2% on Friday. * BETMGM: U.S. sports-betting platform BetMGM, a joint venture between MGM Resorts MGM.N and Entain ENT.L , expects to turn profitable in the second half of 2023. * ROYAL MAIL: British postal firm Royal Mail is resuming some of its international export services two weeks after its operations were disrupted by what it called a "cyber incident." * ASDA
A
R

AstraZeneca Provides Update on Evusheld US EUA

BRIEF-AstraZeneca Provides Update on Evusheld US EUA Jan 26 (Reuters) - AstraZeneca PLC AZN.L : UPDATE ON EVUSHELD US EUA TO CONTINUE TO WORK WITH FDA, OTHER HEALTH AUTHORITIES TO COLLECT, ASSESS, SHARE RELEVANT DATA REGARDING EVUSHELD AND SARS-COV-2 VARIANTS EVUSHELD REMAINS AUTHORISED IN OTHER COUNTRIES WHERE IT IS APPROVED FOR COVID PRE-EXPOSURE
A

U.S. FDA pulls authorization for AstraZeneca's 19 treatment Evusheld

UPDATE 2-U.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment Evusheld Adds share movement, background on variant, Company statement Jan 26 (Reuters) - The U.S. health regulator has withdrawn emergency-use authorization for AstraZeneca's AZN.L COVID-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.
A

U.S. FDA Announces Evusheld Is Not Currently Authorized For Emergency Use In U.S.

BRIEF-U.S. FDA Announces Evusheld Is Not Currently Authorized For Emergency Use In U.S. Jan 26 (Reuters) - FDA: U.S. FDA ANNOUNCES EVUSHELD IS NOT CURRENTLY AUTHORIZED FOR EMERGENCY USE IN U.S. FDA- DATA SHOW EVUSHELD IS UNLIKELY TO BE ACTIVE AGAINST CERTAIN SARS-COV-2 VARIANTS FDA -REVISED EUA FOR EVUSHELD TO LIMIT USE TO WHEN COMBINED FREQUENCY OF NON-SUSCEPTIBLE SARS-COV-2 VARIANTS NATIONALLY IS LESS THAN OR EQUAL TO 90% U.S.
A

U.S. FDA withdraws authorization for AstraZeneca's Evusheld

U.S. FDA withdraws authorization for AstraZeneca's Evusheld Jan 26 (Reuters) - The U.S. Food and Drug Administration said on Thursday that AstraZeneca's AZN.L COVID-19 antibody cocktail Evusheld is not currently authorized for use in the United States until further notice by the agency. Reporting by Bhanvi Satija in Bengaluru
A

AstraZeneca Says Enhertu Approved In EU As The First Directed Therapy For Low Metastatic Breast Cancer

BRIEF-AstraZeneca Says Enhertu Approved In EU As The First HER2-Directed Therapy For HER2-Low Metastatic Breast Cancer Jan 26 (Reuters) - AstraZeneca PLC AZN.L : ENHERTU APPROVED IN THE EU AS THE FIRST HER2-DIRECTED THERAPY FOR PATIENTS WITH HER2-LOW METASTATIC BREAST CANCER APPROVAL BY EUROPEAN COMMISSION FOLLOWS POSITIVE OPINION OF COMMITTEE FOR
A

Thermo Fisher Scientific Partners With Astrazeneca To Develop Solid Tissue And Blood-Based Companion Diagnostic Test For Tagrisso

BRIEF-Thermo Fisher Scientific Partners With Astrazeneca To Develop Solid Tissue And Blood-Based Companion Diagnostic Test For Tagrisso Jan 24 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC PARTNERS WITH ASTRAZENECA TO DEVELOP SOLID TISSUE AND BLOOD-BASED COMPANION DIAGNOSTIC TEST FOR TAGRISSO THERMO FISHER: VIA COLLABORA
A
T

JPMorgan sees potential for $1 trillion equity selling

LIVE MARKETS-JPMorgan sees potential for $1 trillion equity selling STOXX 600 down 0.34% Euro zone PMI returns to growth U.S. stock futures dip Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com JPMORGAN SEES POTENTIAL FOR $1 TRILLION EQUITY SELLING (1304 GMT) Several segments of the market, including European equities, are "trading as if the energy crisis, war, and sharp monetary t
A
A
E
I
M
S
U
V
M
T
E
F
U
A
G

Ibex Medical Analytics Enters Collaboration With AstraZeneca And Daiichi Sankyo

BRIEF-Ibex Medical Analytics Enters Collaboration With AstraZeneca And Daiichi Sankyo Jan 24 (Reuters) - Ibex Medical Analytics: IBEX MEDICAL ANALYTICS: ENTERS COLLABORATION WITH ASTRAZENECA AND DAIICHI SANKYO TO DEVELOP AI-BASED HER2 SCORING PRODUCT Source text for Eikon: ID:nPnwz76pa Further company coverage: AZN.L
A

Eurozone: "Sometimes you just need a bit of luck"

LIVE MARKETS-Eurozone: "Sometimes you just need a bit of luck" STOXX 600 down 0.4% Euro zone PMI returns to growth U.S. stock futures dip Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROZONE: "SOMETIMES YOU JUST NEED A BIT OF LUCK" (1043 GMT) It looks the "no recession in the euro zone" camp is getting bigger by the day.
A
A
E
I
M
S
U
V
M
T
E
F
U
A
G

FTSE 100 dips after weak economic data fans recession fears

UPDATE 2-FTSE 100 dips after weak economic data fans recession fears For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window UK PMI falls at fastest rate in 2 years Senior jumps after upbeat forecast FTSE 100 down 0.4%, FTSE 250 adds 0.3% Updates to market close By Shashwat Chauhan and Shristi Achar A Jan 24 (Reuters) - UK's blue-chip index closed in the red on Tuesday, with healthcare and commodity stocks leading losses after data showed Britis
A
E
G
A
R
U

STOXX dips on healthcare drag

LIVE MARKETS-STOXX dips on healthcare drag Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com STOXX DIPS ON HEALTHCARE DRAG (0912 GMT) European shares slipped just below parity on Tuesday shortly after a slightly positive start, with the STOXX 600 .STOXX last down around 0.1%.
A
M
S
V
M
T
E
F
U
G

AstraZeneca Begins Tender Offer To Acquire CinCor Pharma

BRIEF-AstraZeneca Begins Tender Offer To Acquire CinCor Pharma Jan 23 (Reuters) - AstraZeneca PLC AZN.L : ASTRAZENECA BEGINS TENDER OFFER TO ACQUIRE CINCOR PHARMA, INC. ASTRAZENECA - FOLLOWING SUCCESSFUL CLOSING OF TENDER OFFER, CINCOR WILL BECOME A SUBSIDIARY OF ASTRAZENECA ASTRAZENECA - CINCOR WILL BECOME A SUBSIDIARY OF ASTRAZENECA ASTRAZENECA-THROUGH SUBSIDIARY, TENDER OFFER TO PURCHASE ALL OUTSTANDING SHARES OF CINCOR PHARMA, INC.
A

Wall Street rally keeps Nasdaq Composite above key level

LIVE MARKETS-Wall Street rally keeps Nasdaq Composite above key level Major U.S. stock indexes end green: Nasdaq up ~2.7% All S&P 500 sectors rally: Comm Svcs leads Dollar ~flat; gold slips, crude up; bitcoin rallies ~6% U.S. 10-Year Treasury yield jumps to 3.48% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
A
A
E
G
M
N
S
T
G
U
U
U

S&P 500 earnings estimate weakens in the latest week

LIVE MARKETS-S&P 500 earnings estimate weakens in the latest week Major U.S. stock indexes green; Nasdaq up ~1.7% Comm svcs leads S&P gainers; healthcare weakest group Dollar, crude, bitcoin rise; gold dips U.S. 10-Year Treasury yield jumps to 3.48% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com S&P 500 EARNINGS ESTIMATE WEAKENS IN LATEST WEEK (1330 EST/1830 GMT) The estimated d
A
A
A
E
G
M
N
S
T
G
U
U
U
B

Big Tech to squeeze more revenue per employee with layoffs

LIVE MARKETS-Big Tech to squeeze more revenue per employee with layoffs Major U.S. stock indexes green; Nasdaq up ~1.5% Comm svcs leads S&P gainers; utilities weakest group Dollar, crude, bitcoin rise; gold dips U.S. 10-Year Treasury yield jumps to 3.49% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com BIG TECH TO SQUEEZE MORE REVENUE PER EMPLOYEE WITH LAYOFFS (1245 EST/1745 GMT)
A
A
E
G
M
N
S
G
U
U
U
B

Bulls jump to nine-week high -AAII

LIVE MARKETS-Bulls jump to nine-week high -AAII Major U.S. stock indexes green; Nasdaq up ~1.5% Comm svcs leads S&P gainers; utilities weakest group Dollar, crude, bitcoin rise; gold dips U.S. 10-Year Treasury yield jumps to 3.49% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com BULLS JUMP TO NINE-WEEK HIGH -AAII (1210 EST/1710 GMT) Individual investor optimism over the short-term
A
E
G
N
S
G
U
U
U
B

Biotech off to strong start but rocky recovery seen

LIVE MARKETS-Biotech off to strong start but rocky recovery seen Major U.S. stock indexes green; Nasdaq up ~1.4% Comm svcs leads S&P gainers; utilities weakest group Euro STOXX 600 index up ~0.3% Dollar, crude, bitcoin rise; gold slips U.S. 10-Year Treasury yield rises to 3.50% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
C
E
G
J
N
S
G
U
U
U
F
I
S
U
G
B



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

ہم کوکیز کا استعمال آپکو ہماری ویب سائٹ پر بہتریں تجربہ دینے کیلیے کرتے ہیں۔ مزید پڑھیے یا اپنی کوکی سیٹنگ تبدیل کیجیے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔